Calamenene

Calamenene (0.1-10 μM; 2 days) dose-dependently upregulates the expression of maturation markers (CD1a, CD80, CD83, CD86, HLA-DR) and reduces the endocytic activity in human monocyte-derived dendritic cells^[1].
Calamenene (10 μM; 2 days) induces the maturation of human monocyte-derived dendritic cells. Following stimulation with CD40-L, these cells secrete high levels of Th1-promoting cytokines IL-12p70 and IL-6, as well as low levels of the anti-inflammatory cytokine IL-10, driving allogeneic naive CD4⁺ T cells to differentiate into Th1 cells that secrete high levels of IFN-γ and low levels of IL-4^[1].
Calamenene (10 μM; 2 days) induces the maturation of human monocyte-derived dendritic cells, upregulates the expression of CCR7, enhances their migratory capacity toward MIP-3β, and exhibits stronger intracellular Ca²⁺ mobilization in response to MIP-3β^[1].
Calamenene (0.1-5.0 µg/mL; 1 h at room temperature, followed by 24 h at 28 °C post-plating) inhibits the growth of Vibrio harveyi MMRF1107, and the bacterial mortality increases in a concentration-dependent manner^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.